We have shown previously that CBA/J mice immunized with Candida albicans developed delayed hypersensitivity (DH) demonstrable with mannan (MAN) extracted from the same organism and that the intravenous (i.v.) 
Yeasts, especially Saccharomyces cerevisiae but more recently Candida albicans as well, have been the subject of many studies involving immunoregulation. Of particular interest have been immunomodulations occurring in response to the cell wall or cell wall components of these organisms. In the early 1960s, for example, Riggi and Di Luzio (45) and Wooles and Di Luzio (51) made their initial observations on glucan from the cell wall of S. cerevisiae as an immunostimulant of the reticuloendothelial system, an observation that occasioned much additional research. A few years later, however, a different picture emerged regarding the cell wall of C. albicans, namely that it contained one or more components, initially unidentified but later thought to contain mannan (MAN), which were sloughed during serious disease caused by C. albicans, and that the circulating components resulted in immunosuppression rather than immunoenhancement (5, 31, 38) .
Serum-dependent abnormalities in patients with candidiasis, especially those with chronic mucocutaneous candidiasis (1, 5, (17) (18) (19) 38) , disseminated candidiasis (29) , or chronic vaginal candidiasis (50) , were most often noted at the level of cellular immunity demonstrable either in vivo in tests of delayed hypersensitivity (DH) or in vitro in lymphocyte stimulation assays with peripheral blood leukocytes from patients and healthy donors. In vivo, some patients had complete anergy to all recall antigens, whereas other patients had anergy limited to candidal antigen. In vitro, Candida-specific responses were suppressed frequently as well, but responses of the patient lymphocytes to mitogens were usually normal and noncandidal antigen responses were only occasionally suppressed. In many instances the serum inhibitor was not identified, but in several patients it was theorized to be a circulating component of Candida sp. because either it could be removed by anti-Candida antibodies or it disappeared following remission of the candidiasis. Fischer et al. (18) presented the most convincing evidence that a cell wall component, and in particular MAN, was responsible for at least some of the immunosuppression seen in patients with candidiasis. Of 23 patients studied by these investigators, 6 had serum factors which disappeared after anti-Candida therapy, and when an in-depth study was done with the sera from 3 of the patients, the serum inhibitor was nontoxic, thermostable, nonprecipitable with ammonium sulfate, and could be absorbed out with anti-Candida antibodies and concanavalin A. All of these characteristics were compatible with the inhibitor being MAN or a MAN-containing compound. Recently, Durandy et al. (17) showed that lymphocytes taken from patients during active infection with C. albicans cells were suppressed in their ability to produce antibody to MAN as well.
Since the data acquired from human studies implied that MAN might be responsible for the regulatory phenomena observed in such patients, we began studies in a murine model designed to investigate the immunomodulatory capacity of MAN Mice. Male and female CBA/J mice, 6 to 8 weeks of age (referred to hereafter as adults), were obtained from Jackson Laboratory, Bar Harbor, Maine, for use in specific experiments or as animals for mating in order to obtain infant mice in which long-term colonization with C. albicans or Candida tropicalis could be established as described previously (11, 42) . Specific mating procedures and the procedures for colonization with C. albicans were described previously (11) . The conditions for colonization of infant mice with C. tropicalis were the same as those for colonization with C. albicans. All animals were housed under laminar-flow conditions with negative-pressure air flow and fed mouse chow and water ad libitum.
Culture and fractionation procedures. C. albicans 20A, a serotype A isolate originally obtained from E. Reiss (Centers for Disease Control, Atlanta, Ga.), and C. tropicalis A054, an isolate originally obtained from W. Merz (Johns Hopkins University, Baltimore, Md.), were used for these studies. They were maintained at 4°C by monthly transfer on Sabouraud dextrose agar. Viable blastoconidia for inoculation into mice were grown in Sabouraud dextrose broth for 18 h at 37°C on a gyratory shaker operating at approximately 165 rpm. After three washes in sterile nonpyrogenic saline, the blastoconidia were counted in a hemacytometer and resuspended to the desired concentration in the same diluent for inoculation into animals. Each suspension was diluted further and spread onto Sabouraud dextrose agar plates to determine viable numbers. Viable blastoconidia from which antigens were to be prepared were harvested from 10-liter fermentor (New Brunswick Scientific Co., Edison, N.J.) cultures grown in Trypticase (BBL Microbiology Systems, Cockeysville, Md.) soy dialysate broth (44) , that had been incubated for 18 h at 37°C with constant aeration and agitation, and were washed with 0.15 M phosphate-buffered saline (pH 7.2) containing 0.001 M phenylmethylsulfonyl fluoride. Blastoconidia were stored frozen in phosphatebuffered saline containing the inhibitor before fractionation. MAN was extracted from whole blastoconidia by the method of Peat et al. (40) as modified by Kocourek and Ballou (28) . MAN was dialyzed against distilled water and lyophilized.
Animal inoculations. Infant mice were infected with 2 x 107 viable C. albicans or C. tropicalis blastoconidia by intubation at 5 to 6 days of age with small-bore-diameter polyethylene tubing as described previously (11, 42) . Confirmation of colonization was obtained by fecal culture of intubated animals when they were 4 to 5 weeks of age. Other animals were intubated with 2 x 107 viable C. albicans or C. tropicalis blastoconidia when 7 to 10 weeks of age. Animals intubated with C. tropicalis as adults were treated with trimethoprim-sulfamethoxazole to promote retention of the organism in the gut (13) . In addition, some intubated animals, whether intubated as adults or infants, were inoculated cutaneously on the shaved flank as adults, i.e., >6 weeks of age, with 1.0 x 106 viable C. albicans blastoconidia to boost immunity to readily demonstrable levels (11) . Animals injected with mock-or antibody-treated cells or with MAN received the indicated number of cells or 0.5 to 1.0 mg of MAN i.v. via the lateral tail vein. Preparation and treatment of lymphoid cell suspensions. Naive CBA/J mice were injected i.v. with MAN 1, 4, or 7 days prior to sacrifice. At sacrifice, the spleens were removed for use in single-cell suspensions and prepared in RPMI 1640 (M.A. Bioproducts, Walkersville, Md.), supplemented with 20 mM L-glutamine, 100 ,ug of penicillin and streptomycin per ml (Difco Laboratories, Detroit, Mich.), and 5% heat-inactivated horse serum (Sigma Chemical Co., St. Louis, Mo.). All cell suspensions were passaged through nylon wool for recovery of nonadherent cells as previously described (27) . Erythrocytes were removed by treatment with Gey's solution (33) . Some cell suspensions were prepared in cytotoxicity medium and treated with monoclonal anti-Thy-1.2, anti-Lyt-1.1, anti-Lyt-2.1, or BALB/c control ascites fluid-MA and with Low-Tox-M rabbit complement according to the instructions of the manufacturer (Accurate Chemical and Scientific Corp., Westbury, N.Y.). Cell suspensions treated with BALB/c control ascites fluid and complement are referred to in this study as mock treated. Cell counts done following nylon wool passage were used to calculate the dilutions required for antibody and complement treatment. Viable cells that remained following cytotoxic treatment were suspended to the desired concentration for transfer on the basis of the counts obtained following nylon wool enrichment; i.e., cell suspensions were not recounted following cytotoxic treatment. To ascertain that the control ascites fluid was not anticomplementary, the fluid was shown to lack the ability to block lysis by complement of anti-Thy-treated lymph node lymphocytes.
Footpad testing. DH responses were determined by footpad testing with 0.02 ml of nonpyrogenic saline containing 30 ,ug (wt/vol) of MAN. Footpads were measured with Schnelltaster calipers (H. Kroplein, Schluchtern, Federal Republic of Germany) before injection of antigen and at 15 min and 4, 7, 24, and 48 h after injection. The mean net increase in footpad thickness was determined by subtracting the preinjection measurements from the postinjection measurements. Unimmunized animals were used as controls for the inherent inflammatory capacity of the antigen. Data were analyzed by Student's t test.
Experimental design. The manner in which the animals were immunized and the time selected at which DH was measured were derived from previous studies with CBA/J mice (11, 13, 21, 34) . Animals were immunized by intubation as infant or adult mice. Intubation of either age group resulted in significant priming of Candida-specific responses which were then demonstrable following a single intradermal (i.d.) inoculation (booster) with viable blastoconidia. The booster inoculation was administered to the animals that had been intubated as infants when they were 6 to 8 weeks of age, whereas it was administered to the animals intubated as adults 3 weeks following intubation. Maximum DH responses occurred 1 week following the booster inoculations. MAN was administered i.v. 1 day prior to i.d. inoculation in those animals used as the suppressed controls and 1, 4, or 7 days prior to sacrifice and harvest in naive animals used as the source of suppressor cells. Suppressor cells were transferred to immunized animals 1 day prior to testing such animals for delayed hypersensitivity.
RESULTS
The MAN-induced suppressor cell is a T lymphocyte. It was hypothesized that the MAN-induced suppressor cell was a T lymphocyte. Therefore, experiments were performed (i) to determine if a population of cells containing predominantly T lymphocytes could transfer the suppression to immunized animals and, if transfer of suppression was achieved with such a population, (ii) to determine that abrogation of suppression could be achieved by treatment of the transfer cells with an anti-T-cell reagent. In this series, adult male CBA/J mice were inoculated intragastrically with C. albicans and 3 weeks later were inoculated i.d. as well. One day prior to footpad testing, i.e., 6 days after the i.d. inoculation, 2 x 107 nylon-wool-nonadherent lymphocytes or lymphocytes from normal donors were injected i.v. Minimal suppression was observed in those animals receiving cells from MAN-treated mice, and no suppression was observed in mice receiving lymphocytes from normal animals (data not shown). In the second experiment, the protocol was altered so that the donor animals received 500 ptg of MAN just 1 day prior to sacrifice and transfer. Moreover, nylon-wool-nonadherent cells from both MAN-treated and untreated mice were incubated with antiThy antiserum or mock ascites fluid and complement prior to transfer. Footpad testing was performed 1 day following the transfer of lymphocytes. These data are presented in Fig. 1 .
It is clear from the data (Fig. 1 ) that the MAN-induced, MAN-specific suppressor cells were T lymphocytes. They were present in the nylon-wool-nonadherent suspension prepared from mice treated with 500 jig of MAN 1 day prior to sacrifice, and their activity was abrogated by treatment of nylon-wool-nonadherent lymphocytes from MAN-treated animals with anti-Thy-1 antiserum and complement. Two additional experiments which included donor cells derived from naive animals not treated with MAN were done to confirm that normal cells had no influence on the DH response of immunized animals. In one of the two additional experiments, however, 1 mg of MAN was injected into naive animals 4 days prior to sacrifice and transfer. In all subsequent transfer experiments, in fact, donor mice were treated with 1 mg of MAN 4 days prior to sacrifice and transfer. Since cells from untreated animals did not alter the DH response of recipients in any of these four experiments, those groups of animals were not included in subsequent experiments.
Experiments were also performed to determine the approximate number of cells required to illustrate the suppressor effect in transfer experiments. The experimental protocol was similar to that for which data are presented in Fig. 1 , with the exception that lymphocytes for transfer were obtained from mice injected i.v. with 1 mg of MAN 4 days prior to sacrifice. These experiments are presented in Fig. 2 . A count of 1 x 106 cells was capable of transferring suppression, whereas a count of 2 x 105 cells was not, and when suppression was demonstrated in transfer experiments, that suppression could be abrogated by treatment of the transfer suspension with anti-Thy antiserum and complement. An interesting but as yet unexplained phenomenon occurred in a number of experiments in which nylon-wool-nonadherent cells from MAN-treated donor mice were treated with anti-T-lymphocyte reagents. Those suspensions were no longer capable of transferring suppression, but the animals inoculated with those cells frequently developed DH reactions that were significantly greater than the DH reactions in the immunized control group (see Fig. 1 and 2 ), suggesting that a population of cells remained following cytotoxic treatment that enhanced DH responses in immunized animals.
MAN-induced suppressor cells are T lymphocytes of Lyt-2 phenotype. To determine the Lyt phenotype of the suppressor cells, splenocytes taken from mice treated 4 days previously with 1 mg of MAN were nylon wool passaged and the nonadherent cells were treated with anti-Lyt-1, anti-Lyt-2, or mock antisera and complement before transfer to immunized animals 1 day prior to footpad testing. Two types of animals were used, namely, animals that had been colonized with C. albicans as infants and then boosted i.d. prior to footpad testing (Fig. 3A) and animals that were intubated with C. albicans as adults and then boosted 3 weeks later by i.d. inoculation of viable yeasts (Fig. 3B and C) . Only the responses of male mice are presented in Fig. 3 , although a fourth experiment was performed in which female mice colonized as infants were used as recipients. Abrogation of transfer activity occurred in all experiments when the cell suspensions were treated with anti-Lyt-2. In the two experiments involving male mice colonized as adults ( Fig. 3B and  C) , however, abrogation of suppressor activity also occurred when the transfer suspension was treated with anti-Lyt-1. It is possible that an Lyt-1+2+ cell is an inducer or intermediate cell in the circuit leading to an Lyt-1-2+ cell. Both cells could have functional suppressor activity, or the Lyt-1+2+ cell could induce a functional Lyt-1-2+ suppressor cell in 
DISCUSSION
We have shown in this study that MAN administered i.v. to naive mice induced a population of suppressor T lymphocytes which, when transferred to immunized animals, suppressed the MAN-specific DH responses of the animals. The phenotype of the suppressor cell observed at 4 days was clearly Thy-1+ and Lyt-2+. In some experiments, removal of Lyt-1+ cells also abrogated the ability of the transferred cells to mediate suppression. The presence of each of these phenotypic markers is consistent with our current view of murine suppressor T lymphocytes and the circuits involved in their production (2, 15, 22) . Murine T-cell suppressor circuits described to date have involved at least two cells, an Lyt-1+2-inducer-suppressor and an Lyt-1-2+ effectorsuppressor. In some circuits Lyt-1+2+ cells have been noted, and in others an Lyt-1-2+ intermediate cell between the inducer-suppressor and effector-suppressor, i.e., a transducer cell, has been described as well. In our system, a functional suppressor Lyt-1+2+ cell may act as a precursor to a second functional effector cell in the pathway, the latter having an Lyt-1-2+ phenotype. Alternatively, the Lyt-1+2+ cell could be a nonfunctional transducer cell, exerting its suppressor effect by acting on an undifferentiated population within the recipient to effect suppression. The mouse is known to have a large pluripotent T-cell population of the Lyt-1+2' phenotype (6), which, in fact, accounts for approximately 50% of circulating T cells and which could presumably mature into either helper or suppressor cells. Treatment of the Lyt-1+2+ cell with either anti-Lyt-1 or anti-Lyt-2 would, therefore, abrogate the ability of that cell to mediate suppression. The presence of an Lyt-1+ suppressor cell in some groups of animals and not others may simply reflect the kinetics of the development of suppressor activity in a given group of donor mice. The preceding hypotheses must be considered with the following caveats, however. The Lyt-1 (=Ly-1) antigen is somewhat controversial and is not confined solely to T-lymphocyte populations (30, 32) . Moreover, it should not be equated with the L3T4 antigen, the latter being the murine equivalent of human CD4. We have not yet defined our 4-day suppressor cell with respect to the presence or absence of L3T4 antigen, although it would be expected to be negative. Nevertheless, recognizing the limitations of Lyt-1 phenotyping, it does serve to place newly described regulatory cell populations in the context described previously for fungal (25, 26, (35) (36) (37) and nonfungal (43, 47, 48) systems. Anti-Candida suppressor T-cell activity has been described in several other instances (3, 10, 17, 41) , but only rarely has MAN specifically been implicated as the cause of suppression. A MAN-containing antigen, designated GP, was shown to be suppressive of GP-specific DH in an animal model identical to the one employed in the present study, but the cellular nature of the suppression was not defined (7). When MAN alone was implicated as the suppressive agent in previous studies, it resulted in suppression of MAN-specific antibody production, not DH (17) . By use of an in vitro culture system developed in their laboratory earlier (16) (4, 50) or having the characteristics of B lymphocytes (8, 9, 46) or monocytes (19, 49) , have been described in clinical candidiasis or under in vitro culture conditions. Macrophage suppression described by Fischer et al. (19) was directly attributable to MAN, but suppressor B lymphocytes (8, 9, 46) were the result of stimulation with whole Formalin-treated yeast cells. Nevertheless, it is interesting to note that Cuff et al. (8) have observed that the evolution of the Candidainduced suppressor B lymphocyte was dependent upon a T inducer cell.
Suppressor T cells stimulated by circulating antigen which are capable of dampening inductive or suppressive stages of DH have been described in other fungal systems, e.g., cryptococcosis (35) (36) (37) and paracoccidioidomycosis (25, 26) . In the cryptococcal model, a cascade of suppressor T cells began with a Tsl cell which was Lyt-1+2-I-J+ and then progressed through an Lyt-1-2+ I-J+ Ts2 cell to a final Ts3 effector cell of the same phenotype. Similar Tsl and Ts2 cells have been described in the paracoccidioidal system. It is difficult to compare the suppressor cell described by us with suppressor cells in the cryptococcal or paracoccidioidal systems, since we have not done an in-depth study of The observation that the C. albicans MAN-induced suppressor cell effected suppression of C. tropicalis DH was not unexpected. It has been known for many years that C. albicans and C. tropicalis share common surface epitopes detectable by serology (23) , and Pavliak and Sandala (39) and Garcia-de-Lomas et al. (20) have shown recently, by using an enzyme-linked immunosorbent assay and precipitin methods, cross-reactivity between isolated mannans of the two species. Having common serological epitopes would not mean a priori that the species had common epitopes for DH as well, but since we showed that DH was demonstrable in mice immunized with C. tropicalis by using MAN from either C. albicans or C. tropicalis, it would be logical to assume that C. albicans-induced MAN cells would suppress DH in C. tropicalis-infected mice.
In summary, MAN is a polysaccharide capable of exerting multiple biological effects, and it is likely that its release during disease influences the immunological status of the patient. We have shown that one effect of circulating MAN was T-cell-mediated suppression, but others have shown equally convincing data that MAN exerts an effect on polymorphonuclear leukocytes (52) and monocytes (19) . Clinical observations made in a given patient may well depend upon the specific cell or cells being affected the most by MAN at the time of evaluation of the patient.
